Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

2009
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2015 1
2016 3
2017 3
2018 11
2019 8
2020 5
2021 5
2022 7
2023 8
2024 9
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. Brastianos PK, et al. Among authors: ruff mw. N Engl J Med. 2023 Jul 13;389(2):118-126. doi: 10.1056/NEJMoa2213329. N Engl J Med. 2023. PMID: 37437144 Free PMC article. Clinical Trial.
Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma.
Sakemura R, Hefazi M, Siegler EL, Cox MJ, Larson DP, Hansen MJ, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Nevala WK, Walters DK, Parikh SA, Lin Y, Jelinek DF, Kay NE, Bergsagel PL, Kenderian SS. Sakemura R, et al. Among authors: ruff mw. Blood. 2022 Jun 30;139(26):3708-3721. doi: 10.1182/blood.2021012811. Blood. 2022. PMID: 35090171 Free PMC article.
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
Sakemura RL, Manriquez Roman C, Horvei P, Siegler EL, Girsch JH, Sirpilla OL, Stewart CM, Yun K, Can I, Ogbodo EJ, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Hefazi M, Ruff MW, Kimball BL, Mai LK, Huynh TN, Nevala WK, Ilieva K, Augsberger C, Patra-Kneuer M, Schanzer J, Endell J, Heitmüller C, Steidl S, Parikh SA, Ding W, Kay NE, Nowakowski GS, Kenderian SS. Sakemura RL, et al. Among authors: ruff mw. Blood. 2024 Jan 18;143(3):258-271. doi: 10.1182/blood.2022018905. Blood. 2024. PMID: 37879074 Free PMC article.
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management.
Khurana A, Rosenthal AC, Mohty R, Gaddam M, Bansal R, Hathcock MA, Nedved AN, Durani U, Iqbal M, Wang Y, Paludo J, Villasboas JC, Dingli D, Kourelis T, Leung N, Alkhateeb H, Ruff MW, Gallo de Moraes A, Vergidis P, Herrmann J, Kenderian SS, Bennani NN, Johnston PB, Ansell SM, Lin Y. Khurana A, et al. Among authors: ruff mw. Blood Cancer J. 2024 Aug 12;14(1):136. doi: 10.1038/s41408-024-01119-2. Blood Cancer J. 2024. PMID: 39134524 Free PMC article. No abstract available.
AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells.
Sakemura RL, Hefazi M, Cox MJ, Siegler EL, Sinha S, Hansen MJ, Stewart CM, Feigin JM, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Forsman CL, Nevala WK, Boysen JC, Tschumper RC, Grand CL, Kuchimanchi KR, Mouritsen L, Foulks JM, Warner SL, Call TG, Parikh SA, Ding W, Kay NE, Kenderian SS. Sakemura RL, et al. Among authors: ruff mw. Cancer Immunol Res. 2023 Sep 1;11(9):1222-1236. doi: 10.1158/2326-6066.CIR-22-0254. Cancer Immunol Res. 2023. PMID: 37378662 Free PMC article.
Neuro-oncology: Implications of the molecular era.
Ruff MW, Uhm JH, Benarroch EE. Ruff MW, et al. Neurology. 2019 Mar 19;92(12):568-574. doi: 10.1212/WNL.0000000000007126. Epub 2019 Feb 13. Neurology. 2019. PMID: 30760635
54 results